|Bid||2.4800 x 4000|
|Ask||2.4900 x 1200|
|Day's Range||2.4300 - 2.5100|
|52 Week Range||2.2100 - 7.3400|
|Beta (3Y Monthly)||2.65|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
On CNBC's "Mad Money Lightning Round," Jim Cramer said he likes Yeti Holdings Inc (NYSE: YETI ) very much. He believes the stock is undervalued and he sees it as a long-time hold. Daktronics, ...
TherapeuticsMD Inc NASDAQ/NGS:TXMDView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is extremely high for TXMD with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TXMD. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding TXMD is favorable, with net inflows of $2.51 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
TherapeuticsMD (TXMD) grants exclusive commercialization rights to its drugs, Bijuva and Imvexxy, to Theramex in ex-U.S. markets except for Canada and Israel.
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 5.88% and -41.61%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Boca Raton, Florida-based company said it had a loss of 16 cents per share. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.
Legendary investors such as Jeffrey Talpins and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don't publish. Small cap stocks -especially when they are screened well- can generate substantial outperformance versus a boring index fund. That's why we analyze the […]
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rob Finizio has been the CEO of TherapeuticsMD, Inc. (NASDAQ:TXMD) since 2011. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we'll consider grow...
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 21.) Eli Lilly And Co (NYSE: LLY ) Gossamer ...
On a per-share basis, the Boca Raton, Florida-based company said it had a loss of 17 cents. The results matched Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! While small-cap stocks, such as TherapeuticsMD, Inc. (NASDAQ:TXMD) with itsRead More...